Adagene (ADAG) vs Journey Medical (DERM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed Journey Medical (DERM) over the past year, gaining 42.2% versus a loss of 20.9%. Adagene is the larger company by market cap ($185.3 million vs $178.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | DERM |
|---|---|---|
| Share price | $2.76 | $6.31 |
| Market cap | $185.32M | $178.10M |
| 1-day change | -0.72% | +6.05% |
| YTD return | +47.09% | -22.83% |
| 1-year return | +42.20% | -20.88% |
| 5-year return | -76.24% | — |
| EPS (TTM) | $-0.37 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $9.56 |
| 52-week low | $1.30 | $4.31 |
| Distance from 52-week high | -43.09% | -33.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +259.06% | +117.91% |
| Average volume | 244.76K | 184.01K |
| Shares outstanding | 67.14M | 22.22M |
| Employees | 128 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed DERM by 63.1 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ADAG vs DERM FAQ
Which is bigger, Adagene or Journey Medical?
Adagene (ADAG) is larger, with a market capitalization of $185.32M compared with $178.10M for Journey Medical (DERM).
Which stock has performed better over the past year, ADAG or DERM?
ADAG returned +42.20% over the past 12 months, compared with -20.88% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Journey Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.